The use of Cox-2 and PPARγ signaling in anti-cancer therapies (Review)

Knopfová,Lucia; Šmarda,Jan

doi:10.3892/etm_00000040

The use of Cox-2 and PPARγ signaling in anti-cancer therapies (Review)

Authors:
- Lucia Knopfová
- Jan Šmarda
View Affiliations

Affiliations: Department of Experimental Biology, Faculty of Science, Masaryk University, 611 37 Brno, Czech Republic
Published online on: March 1, 2010 https://doi.org/10.3892/etm_00000040
Pages: 257-264

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increased production of the pro-inflammatory enzyme cyclooxygenase-2 (Cox-2) and altered expression and activity of peroxisome proliferator-activated receptor γ (PPARγ) have been observed in many malignancies. Both the PPARγ ligands and the Cox-2 inhibitors possess anti-inflammatory and anti-neoplastic effects in vitro and have been assessed for their therapeutic potential in several pre-clinical and clinical studies. Recently, multiple interactions between PPARγ and Cox-2 signaling pathways have been revealed. Understanding of the cross-talk between PPARγ and Cox-2 might provide important novel strategies for the effective treatment and/or prevention of cancer. This article summarizes recent achievements involving the functional interactions between the PPARγ and Cox-2 signaling pathways and discusses the implications of such interplay for clinical use.

View Figures

View References

1.	Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB and De Marzo AM: Cyclooxygenases in cancer: progress and perspective. Cancer Lett. 215:1–20. 2004. View Article : Google Scholar : PubMed/NCBI
2.	Liao Z, Mason KA and Milas L: Cyclo-oxygenase-2 and its inhibition in cancer: is there a role? Drugs. 67:821–845. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Koehne CH and Dubois RN: COX-2 inhibition and colorectal cancer. Semin Oncol. 31:12–21. 2004. View Article : Google Scholar
4.	Khuder SA and Mutgi AB: Breast cancer and NSAID use: a meta-analysis. Br J Cancer. 84:1188–1192. 2001. View Article : Google Scholar : PubMed/NCBI
5.	Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC and Ross RK: Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer. 82:1364–1369. 2000.PubMed/NCBI
6.	Sooriakumaran P, Langley SE, Laing RW and Coley HM: COX-2 inhibition: a possible role in the management of prostate cancer? J Chemother. 19:21–32. 2007. View Article : Google Scholar : PubMed/NCBI
7.	Muscat JE, Chen SQ, Richie JP Jr, Altorki NK, Citron M, Olson S, Neugut AI and Stellman SD: Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. Cancer. 97:1732–1736. 2003. View Article : Google Scholar : PubMed/NCBI
8.	Sandler AB and Dubinett SM: COX-2 inhibition and lung cancer. Semin Oncol. 31:45–52. 2004. View Article : Google Scholar : PubMed/NCBI
9.	Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK and Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 342:1946–1952. 2000. View Article : Google Scholar : PubMed/NCBI
10.	Suzuki R, Yamamoto M, Saka H, Taniguchi H, Shindoh J, Tanikawa Y, Nomura F, Gonda H, Imaizumi K, Hasegawa Y and Shimokata K: A phase II study of carboplatin and paclitacel with meloxicam. Lung Cancer. 63:72–76. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Soriano F, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr and Chou TC: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 59:6178–6184. 1999.PubMed/NCBI
12.	Tuettenberg J, Grobholz R, Korn T, Wenz F, Erber R and Vajkoczy P: Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol. 131:31–40. 2005. View Article : Google Scholar : PubMed/NCBI
13.	Tachimori A, Yamada N, Amano R, Ohira M and Hirakawa K: Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma. Anticancer Res. 28:629–638. 2008.PubMed/NCBI
14.	Eichele K, Ramer R and Hinz B: Decisive role of cyclooxygenase-2 and lipocalin-type prostaglandin D synthase in chemotherapeutic-induced apoptosis of human cervical carcinoma cells. Oncogene. 27:3032–3044. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ and Willoughby DA: Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med. 5:698–701. 1999. View Article : Google Scholar : PubMed/NCBI
16.	Issemann I and Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 347:645–650. 1990. View Article : Google Scholar : PubMed/NCBI
17.	Nosjean O and Boutin JA: Natural ligands of PPARγ: Are prostaglandin J2 derivatives really playing the part? Cell Signal. 14:573–583. 2002.
18.	Bull AW, Steffensen KR, Leers J and Rafter JJ: Activation of PPAR gamma in colon tumor cell lines by oxidized metabolites of linoleic acid, endogenous ligands for PPAR gamma. Carcinogenesis. 24:1717–1722. 2003. View Article : Google Scholar : PubMed/NCBI
19.	Kepez A, Oto A and Dagdelen S: Peroxisome proliferator-activated receptor-gamma: novel therapeutic target linking adiposity, insulin resistance and atherosclerosis. BioDrugs. 20:121–135. 2006.
20.	Chiarelli F and Di Marzio D: Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives. Vasc Health Risk Manag. 4:297–304. 2008.PubMed/NCBI
21.	Quinn CE, Hamilton PK, Lockhart CJ and McVeigh GE: Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol. 153:636–645. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Konstantinopoulos PA, Vandoros GP, Sotiropoulou-Bonikou G, Kominea A and Papavassiliou AG: NF-κB/PPARγ and/or AP-1/PPARγ ‘on/off’ switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression. Int J Colorectal Dis. 22:57–68. 2007.
23.	Badawi AF and Badr MZ: Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma and levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human breast cancer and metastasis. Int J Cancer. 103:84–90. 2003. View Article : Google Scholar
24.	Nagata D, Yoshihiro H, Nakanishi M, Naruyama H, Okada S, Ando R, Tozawa K and Kohri K: Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer. Cancer Detect Prev. 32:259–266. 2008. View Article : Google Scholar : PubMed/NCBI
25.	Matsuyama M and Yoshimura R: Peroxisome proliferator-activated receptor-gamma is a potent target for prevention and treatment in human prostate and testicular cancer. PPAR Res. 2008:2498492008. View Article : Google Scholar : PubMed/NCBI
26.	Segawa Y, Yoshimura R, Hase T, Nakatani T, Wada S, Kawahito Y, Kishimoto T and Sano H: Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate. 51:108–116. 2002. View Article : Google Scholar : PubMed/NCBI
27.	Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, Okuyama T, Rumi MA, Fukuda R, Nagasue N and Kinoshita Y: Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer. 83:1394–1400. 2000. View Article : Google Scholar : PubMed/NCBI
28.	Inoue K, Kawahito Y, Tsubouchi Y, Yamada R, Kohno M, Hosokawa Y, Katoh D, Bishop-Bailey D, Hla T and Sano H: Expression of peroxisome proliferator-activated receptor (PPAR)-gamma in human lung cancer. Anticancer Res. 21:2471–2476. 2001.PubMed/NCBI
29.	Kristiansen G, Jacob J, Buckendahl AC, Grützmann R, Alldinger I, Sipos B, Klöppel G, Bahra M, Langrehr JM, Neuhaus P, Dietel M and Pilarsky C: Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin Cancer Res. 12:6444–6451. 2006. View Article : Google Scholar
30.	Vignati S, Albertini V, Rinaldi A, Kwee I, Riva C, Oldrini R, Capella C, Bertoni F, Carbone GM and Catapano CV: Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia. 8:851–861. 2006. View Article : Google Scholar : PubMed/NCBI
31.	Jung TI, Baek WK, Suh SI, Jang BC, Song DK, Bae JH, Kwon KY, Bae JH, Cha SD, Bae I and Cho CH: Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma. Gynecol Oncol. 97:365–373. 2005. View Article : Google Scholar : PubMed/NCBI
32.	Grommes C, Landreth GE and Heneka MT: Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 5:419–429. 2004. View Article : Google Scholar : PubMed/NCBI
33.	Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP and Standiford TJ: Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene. 23:100–108. 2004. View Article : Google Scholar : PubMed/NCBI
34.	Yasui Y, Kim M and Tanaka T: PPAR ligands for cancer chemoprevention. PPAR Res. 2008:5489192008. View Article : Google Scholar : PubMed/NCBI
35.	Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM and Kantoff PW: Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA. 97:10990–10995. 2000. View Article : Google Scholar : PubMed/NCBI
36.	Rumi MA, Ishihara S, Kazumori H, Kadowaki Y and Kinoshita Y: Can PPAR gamma ligands be used in cancer therapy? Curr Med Chem Anticancer Agents. 4:465–477. 2004. View Article : Google Scholar : PubMed/NCBI
37.	Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R and Auwerx J: Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med. 4:1053–1057. 1998.PubMed/NCBI
38.	Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA and Evans RM: Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med. 4:1058–1061. 1998. View Article : Google Scholar : PubMed/NCBI
39.	Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E, Nelson M, Banayo E, Cardiff RD, Izpisua-Belmonte JC and Evans RM: PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev. 18:528–540. 2004. View Article : Google Scholar : PubMed/NCBI
40.	Eibl G: The role of PPAR-gamma and its interaction with COX-2 in pancreatic cancer. PPAR Res. 2008:3269152008. View Article : Google Scholar : PubMed/NCBI
41.	Kawashima A, Harada T, Imada K, Yano T and Mizuguchi K: Eicosapentaenoic acid inhibits interleukin-6 production in interleukin-1beta-stimulated C6 glioma cells through peroxisome proliferator-activated receptor-gamma. Prostaglandins Leukot Essent Fatty Acids. 79:59–65. 2008. View Article : Google Scholar
42.	Allred CD, Talbert DR, Southard RC, Wang X and Kilgore MW: PPARgamma1 as a molecular target of eicosapentaenoic acid in human colon cancer (HT-29) cells. J Nutr. 138:250–256. 2008.PubMed/NCBI
43.	Straus DS and Glass CK: Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev. 21:185–210. 2001. View Article : Google Scholar : PubMed/NCBI
44.	Matsuoka T and Narumiya S: Prostaglandin receptor signaling in disease. ScientificWorldJournal. 7:1329–1347. 2007. View Article : Google Scholar
45.	Castellone MD, Teramoto H, Williams BO, Druey KM and Gutkind JS: Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science. 310:1504–1510. 2005. View Article : Google Scholar : PubMed/NCBI
46.	Chan TA: Prostaglandins and the colon cancer connection. Trends Mol Med. 12:240–244. 2006. View Article : Google Scholar : PubMed/NCBI
47.	Scher JU and Pillinger MH: 15d-PGJ2: the anti-inflammatory prostaglandin? Clin Immunol. 114:100–109. 2005. View Article : Google Scholar : PubMed/NCBI
48.	Shimada T, Kojima K, Yoshiura K, Hiraishi H and Terano A: Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand-induced apoptosis in colon cancer cells. Gut. 50:658–664. 2002. View Article : Google Scholar
49.	Millan O, Rico D, Peinado H, Zarich N, Stamatakis K, Pérez-Sala D, Rojas JM, Cano A and Boscá L: Potentiation of tumor formation by topical administration of 15-deoxy-delta12,14-prostaglandin J2 in a model of skin carcinogenesis. Carcinogenesis. 27:328–336. 2006. View Article : Google Scholar : PubMed/NCBI
50.	Chinery R, Coffey RJ, Graves-Deal R, Kirkland SC, Sanchez SC, Zackert WE, Oates JA and Morrow JD: Prostaglandin J2 and 15-deoxy-delta12,14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Res. 59:2739–2746. 1999.PubMed/NCBI
51.	Reginato MJ, Krakow SL, Bailey ST and Lazar MA: Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J Biol Chem. 273:1855–1858. 1998. View Article : Google Scholar
52.	Padilla J, Kaur K, Cao HJ, Smith TJ and Phipps RP: Peroxisome proliferator activator receptor-gamma agonists and 15-deoxy-delta(12,14)(12,14)-PGJ(2) induce apoptosis in normal and malignant B-lineage cells. J Immunol. 165:6941–6948. 2000. View Article : Google Scholar : PubMed/NCBI
53.	Jaradat MS, Wongsud B, Phornchirasilp S, Rangwala SM, Shams G, Sutton M, Romstedt KJ, Noonan DJ and Feller DR: Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen and indomethacin. Biochem Pharmacol. 62:1587–1595. 2001. View Article : Google Scholar : PubMed/NCBI
54.	Lehmann JM, Lenhard JM, Oliver BB, Ringold GM and Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 272:3406–3410. 1997. View Article : Google Scholar
55.	López-Parra M, Clària J, Titos E, Planagumà A, Párrizas M, Masferrer JL, Jiménez W, Arroyo V, Rivera F and Rodés J: The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARgamma. Influence of albumin. J Hepatol. 42:75–81. 2005.PubMed/NCBI
56.	Diamond MP and Saed G: Modulation of the expression of peroxisome proliferator-activated receptors in human fibroblasts. Fertil Steril. 87:706–709. 2007. View Article : Google Scholar : PubMed/NCBI
57.	Shaik MS, Chatterjee A and Singh M: Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma. Clin Cancer Res. 10:1521–1529. 2004. View Article : Google Scholar
58.	Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S and Kawai S: Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther. 302:18–25. 2002. View Article : Google Scholar
59.	Cui W, Yu CH and Hu KQ: In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res. 11:8213–8221. 2005. View Article : Google Scholar : PubMed/NCBI
60.	Nagahara T, Okano J and Murawaki Y: Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells. Oncol Rep. 18:1281–1290. 2007.PubMed/NCBI
61.	Meade EA, McIntyre TM, Zimmerman GA and Prescott SM: Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem. 274:8328–8334. 1999. View Article : Google Scholar : PubMed/NCBI
62.	Pontsler AV, St Hilaire A, Marathe GK, Zimmerman GA and McIntyre TM: Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein. J Biol Chem. 277:13029–13036. 2002. View Article : Google Scholar : PubMed/NCBI
63.	Bishop-Bailey D and Warner TD: PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist. FASEB J. 17:1925–1927. 2003.
64.	Kalajdzic T, Faour WH, He QW, Fahmi H, Martel-Pelletier J, Pelletier JP and Di Battista JA: Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism. Arthritis Rheum. 46:494–506. 2002. View Article : Google Scholar
65.	Lee JH, Yu SM, Yoon EK, Lee WK, Jung JC and Kim SJ: 15-Deoxy-delta 12,14-prostaglandin J2 regulates dedifferentiation through peroxisome proliferator-activated receptor-gamma-dependent pathway but not COX-2 expression in articular chondrocytes. J Korean Med Sci. 22:891–897. 2007. View Article : Google Scholar
66.	Patel KM, Wright KL, Whittaker P, Chakravarty P, Watson ML and Ward SG: Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPAR(gamma) agonists: evidence for disparate functional effects which are independent of NF-(kappa)B and PPAR(gamma). Cell Signal. 17:1098–1110. 2005. View Article : Google Scholar
67.	Chêne G, Dubourdeau M, Balard P, Escoubet-Lozach L, Orfila C, Berry A, Bernad J, Aries MF, Charveron M and Pipy B: n-3 and n-6 polyunsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaT cells. Biochim Biophys Acta. 1771:576–589. 2007.PubMed/NCBI
68.	Pang L, Nie M, Corbett L and Knox AJ: Cyclooxygenase-2 expression by nonsteroidal anti-inflammatory drugs in human airway smooth muscle cells: role of peroxisome proliferator-activated receptors. J Immunol. 170:1043–1051. 2003. View Article : Google Scholar : PubMed/NCBI
69.	Ulivi V, Cancedda R and Cancedda FD: 15-Deoxy-delta 12,14-prostaglandin J(2) inhibits the synthesis of the acute phase protein SIP24 in cartilage: involvement of COX-2 in resolution of inflammation. J Cell Physiol. 217:433–441. 2008. View Article : Google Scholar : PubMed/NCBI
70.	Li Z, Jansen M, Ogburn K, Salvatierra L, Hunter L, Mathew S and Figueiredo-Pereira ME: Neurotoxic prostaglandin J2 enhances cyclooxygenase-2 expression in neuronal cells through the p38MAPK pathway: a death wish? J Neurosci Res. 78:824–836. 2004. View Article : Google Scholar : PubMed/NCBI
71.	Ulivi V, Giannoni P, Gentili C, Cancedda R and Descalzi F: p38/NF-κB-dependent expression of COX-2 during differentiation and inflammatory response of chondrocytes. J Cell Biochem. 104:1393–1406. 2008.PubMed/NCBI
72.	Tsatsanis C, Androulidaki A, Venihaki M and Margioris AN: Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol. 38:1654–1661. 2006. View Article : Google Scholar : PubMed/NCBI
73.	Paik JH, Ju JH, Lee JY, Boudreau MD and Hwang DH: Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways. J Biol Chem. 275:28173–28179. 2000.
74.	Boyault S, Simonin MA, Bianchi A, Compe E, Liagre B, Mainard D, Becuwe P, Dauca M, Netter P, Terlain B and Bordji K: 15-Deoxy-Δ12;14-PGJ2, but not troglitazone, modulates IL-1β effects in human chondrocytes by inhibiting NF-κB and AP-1 activation pathways. FEBS Lett. 501:24–30. 2001.
75.	Liu JJ, Liu PQ, Lin DJ, Xiao RZ, Huang M, Li XD, He Y and Huang RW: Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-gamma agonists induced apoptosis in human monocyte leukemia cells in vitro. Ann Hematol. 86:173–183. 2007. View Article : Google Scholar
76.	Hazra S and Dubinett SM: Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells. Prostaglandins Leukot Essent Fatty Acids. 77:51–58. 2007. View Article : Google Scholar : PubMed/NCBI
77.	Bren-Mattison Y, Meyer AM, van Putten V, Li H, Kuhn K, Stearman R, Weiser-Evans M, Winn RA, Heasley LE and Nemenoff RA: Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol. 73:709–717. 2008. View Article : Google Scholar
78.	Delerive P, Gervois P, Fruchart JC and Staels B: Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem. 275:36703–36707. 2000. View Article : Google Scholar
79.	Moraes LA, Piqueras L and Bishop-Bailey D: Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther. 110:371–385. 2006. View Article : Google Scholar
80.	Wahli W: A gut feeling of the PXR, PPAR and NF-κB connection. J Intern Med. 263:613–619. 2008.PubMed/NCBI
81.	Ricote M, Li AC, Willson TM, Kelly CJ and Glass CK: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 391:79–82. 1998.
82.	Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M and Santoro MG: Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature. 403:103–108. 2000. View Article : Google Scholar : PubMed/NCBI
83.	Ackerman WE, Zhang XL, Rovin BH and Kniss DA: Modulation of cytokine-induced cyclooxygenase 2 expression by PPARG ligands through NFκB signal disruption in human WISH and amnion cells. Biol Reprod. 73:527–535. 2005.PubMed/NCBI
84.	Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy LL, Ghosh G and Glass CK: 15-Deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway. Proc Natl Acad Sci USA. 97:4844–4849. 2000.
85.	Badawi AF and Badr MZ: Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-γ. Int J Oncol. 20:1109–1122. 2002.
86.	Michael MS, Badr MZ and Badawi AF: Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-γ synergistically induces apoptosis and inhibits growth of human breast cancer cells. Int J Mol Med. 11:733–736. 2003.
87.	Badawi AF, Eldeen MB, Liu Y, Ross EA and Badr MZ: Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Res. 64:1181–1189. 2004. View Article : Google Scholar : PubMed/NCBI
88.	Mustafa A and Kruger WD: Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer. Clin Cancer Res. 14:4935–4942. 2008. View Article : Google Scholar
89.	Sun WH, Chen GS, Ou XL, Yang Y, Luo C, Zhang Y, Shao Y, Xu HC, Xiao B, Xue YP, Zhou SM, Zhao QS and Ding GX: Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells. Cancer Lett. 275:247–255. 2009. View Article : Google Scholar
90.	Narayanan NK, Narayanan BA and Reddy BS: A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-κB, and steroid hormone receptors. Int J Oncol. 26:785–792. 2005.PubMed/NCBI
91.	Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Wang W, Lönnroth C and Lundholm K: EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer. 121:232–240. 2007. View Article : Google Scholar : PubMed/NCBI
92.	Hazra S, Peebles KA, Sharma S, Mao JT and Dubinett SM: The role of PPARgamma in the cyclooxygenase pathway in lung cancer. PPAR Res. 2008:7905682008. View Article : Google Scholar : PubMed/NCBI
93.	Sasaki H, Tanahashi M, Yukiue H, Moiriyama S, Kobayashi Y, Nakashima Y, Kaji M, Kiriyama M, Fukai I, Yamakawa Y and Fujii Y: Decreased peroxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer. Lung Cancer. 36:71–76. 2002. View Article : Google Scholar